FPA deformations may contribute to arterial wall injury and intimal hyperplasia. We measured limb flexion-induced deformations of human cadaveric FPAs before and after stenting with seven different commercially available peripheral artery stents.
FPA deformations may contribute to arterial wall injury and intimal hyperplasia. We measured limb flexion-induced deformations of human cadaveric FPAs before and after stenting with seven different commercially available peripheral artery stents.
Methods: Retrievable nitinol markers were deployed into 28 in situ FPAs of 14 human cadavers. Limbs were perfused with 37 C fluid, and thin-section computed tomography images were acquired with limbs in the standing (180 ), walking (110 ), sitting (90 ) and gardening (60 ) postures. Image segmentation and analysis allowed comparison of relative spatial locations of each intra-arterial marker for determination of baseline FPA axial compression, bending, and torsion. Markers were then retrieved from the arteries, and the FPAs were stented with preand post-balloon dilatation. Zilver, Absolute Pro, Innova, Smart Control, SmartFlex, Supera stents, and Viabahn stent grafts were deployed across the adductor hiatus. Four unique limbs received each stent type with only one stent type per artery. After stenting, markers were redeployed in stented FPAs and imaged in the same postures. Comparison of the baseline and stented FPA deformations allowed determination of the influence of specific stent type (Fig) .
Results: Smart Control, Smart Flex, Zilver, Supera, and Absolute Pro restricted axial compression of the FPA within the stented segment by 56%, 45%, 42%, 26%, and 22%, respectively (P < .05). Smart Flex, Smart Control, and Zilver exacerbated FPA compression distal to the stent by 61% (P < .01), while no differences were observed proximally. Within the stented segment, maximum torsion was restricted by Supera 4 to 12 / cm (P < .05), and exacerbated by Smart Flex 10 to 15 /cm (P < .05). Torsion of the FPA proximal and distal to the stented region was not affected by stenting. Stents reduced bending of the FPA by an average of 42% (P < .01) within the stented segment, but no differences were observed proximally or distally.
Conclusions: Different stent designs significantly affect limb flexioninduced deformations of the FPA not only within the stented segment but also distal to it. Stents that better match natural limb flexion-induced FPA deformations may mitigate arterial injury and potentially improve clinical outcomes of endovascular peripheral artery disease treatments. These data can be used to help more rationally select stent designs specific to arterial segments and patient conditions. Objectives: Fenestrated endovascular aneurysm repair (FEVAR) has expanded the indications of this minimally invasive approach to include patients with pararenal aneurysms. However, it takes about 4 to 6 weeks to manufacture these grafts. The actual cost of this relatively newer technology has not been studied before. The aim of this study was to analyze the cost for patients undergoing FEVAR vs standard endovascular aneurysm repair (EVAR) for nonruptured abdominal aortic aneurysms (AAA).
Methods: Using the Premier Database (2011 Database ( -2015 , we identified all patients who underwent elective EVAR and FEVAR. Student t-tests, c 2 , medians test, and univariate and multivariate generalized linear modeling were implemented to examine in-hospital cost adjusting for patients' demographics and regional characteristics.
Results: A total of 22,497 elective endovascular AAA repairs were performed. Of these, 1719 (7.6%) underwent FEVAR and 20,778 (92.4%) standard EVAR. The majority of patients undergoing FEVAR were white (86% vs 84%; P ¼ .001) and more likely to be smokers (61% vs 58%; P < .03). Both groups had similar comorbidities, except for cerebrovascular disease, which was higher among patients undergoing FEVAR (8% vs 6%; P ¼ .002). The rates of any complication (11% vs 10%), renal (6% vs 4%), and neurologic injury (0.5% vs 0.2%) were higher in the FEVAR group (all P < .05). No differences in mortality (0.8% vs 0.6%), cardiac (4.7% vs 4.4%), respiratory (2.4% vs 2.1%), and gastrointestinal (1.5% vs 1.1%) complications were observed between the two groups (all P > .05). The median total cost and variable cost of the treatment was significantly higher among patients undergoing FEVAR; however, no difference was seen in the fixed cost between the groups (Fig) . After adjusting for patients' characteristics and comorbidities, the multivariate analysis showed that the cost of FEVAR was on average $1569 higher than EVAR (95% confidence interval, 981-2158; P < .001). Additionally, the adjusted average cost of any endovascular AAA repair was higher among blacks and sicker patients and higher across all regions as compared to the Midwest (Table) .
Conclusions: In this large cohort of elective endovascular AAA repair, we showed that the total cost of FEVAR is significantly higher than the cost of standard EVARs, despite adjusting for patient's demographics and comorbidities. This is likely driven by the additional cost of fenestrated endografts and by the increase rate of complications related to FEVAR such as higher renal and neurological injuries. Marked racial and regional disparity in the cost exists among patients undergoing endovascular AAA repair in the United States. 
